David Gu

David Gu is currently the CFO at EpimAb Biotherapeutics. Prior to this, they were a Therapeutics Analyst at Passaic Capital from July 2018 to March 2020. David also worked as an Analyst at Thirty30 Capital from January 2018 to July 2018. For Jefferies & Company, they served as Vice President from July 2013 to January 2018. David Gu began their career in the financial industry as an Associate Analyst at Wells Fargo Securities from July 2010 to June 2013. Before that, they worked as an Associate at McKinsey & Company from September 2008 to April 2010, where they focused on the pharmaceutical and medical device sectors.

David Gu received a B.S. in Biochemistry from the University of Illinois Urbana-Champaign and a Ph.D. in Pharmaceutical Sciences from the University of Michigan.